Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
UCBSTU:UNC -2.74%85 EV-to-OCF is 21.47 as of Sep. 09, 2026, which is 40% above its 10-year median of 15.32. GuruFocus rates STU:UNC with a GF Score™ of 85/100 and a GF Value™ of €251.74 (Modestly Undervalued). Among 1,404 Biotechnology companies, UCB ranks worse than 89.1% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, UCB's Enterprise Value is €41,848 Mil.
UCB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €1,949 Mil. Therefore, UCB's EV-to-OCF for today is 21.47.
The historical rank and industry rank for UCB's EV-to-OCF or its related term are showing as below:
STU:UNC'
s EV-to-OCF Range Over the Past 10 Years
Min: 5.59 Med: 15.32 Max: 52.02
Current: 21.83
During the past 13 years, the highest EV-to-OCF of UCB was 52.02. The lowest was 5.59. And the median was 15.32.
STU:UNC's EV-to-OCF is ranked worse than 89.1% of 1404
companies
in the Biotechnology industry
Industry Median: -3.65
vs STU:UNC: 21.83
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-09-09), UCB's stock price is €205.80.
UCB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €11.320. Therefore, UCB's PE Ratio (TTM) for today is 18.18.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
UCB's share price for today is €205.80.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. UCB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €11.320.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
UCB EV-to-OCF Related Terms
UCB EV-to-OCF Historical Data
* Premium members only.
The historical data trend for UCB's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, UCB's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UCB EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UCB's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where UCB's EV-to-OCF falls into.
UCB's current Enterprise Value is €41,848 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. UCB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €1,949 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UCB (STU:UNC) has a EV-to-OCF of 21.47 as of Sep. 09, 2026. This is 40% above median its historical median of 15.32. Over the past decade, UCB's EV-to-OCF has ranged from 5.59 to 52.02. According to the industry distribution chart, UCB ranks #1251 out of 1404 companies in the Biotechnology industry, placing it in the top 89.1%.
Is UCB's EV-to-OCF too high?
UCB's current EV-to-OCF of 21.47 is 40% above median its 10-year median of 15.32. Over the past 10 years, this metric has ranged from a low of 5.59 to a high of 52.02. Based on the distribution chart, UCB ranks #1251 out of 1404 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, UCB has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does UCB's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, UCB ranks #1251 out of 1404 companies for EV-to-OCF. This places UCB in the lower half of its industry. Historically, UCB's own EV-to-OCF has ranged from 5.59 to 52.02 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. UCB's current EV-to-OCF is 21.47, which is 40% above median its own 10-year median of 15.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UCB stock overvalued right now?
Based on GuruFocus' analysis, UCB (STU:UNC) is currently considered Modestly Undervalued. The stock's GF Value™ is €251.74, compared to a current price of €205.80 — trading 18.2% below its estimated fair value. The current EV-to-OCF is 21.47, which is 40% above median its 10-year median of 15.32. UCB's overall GF Score™ is 85/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For UCB (STU:UNC), the current EV-to-OCF is 21.47 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UCB (STU:UNC) Overvalued in 2026?
Based on GuruFocus' analysis, UCB stock appears to be undervalued.
The current stock price of €205.80 is trading 18.2% below its estimated GF Value™ of €251.74.
GuruFocus considers UCB to be Modestly Undervalued.
Key valuation signals for STU:UNC:
EV-to-OCF: 21.47 (40% above median its 10-year median of 15.32)
GF Value™: €251.74 vs. price of €205.80 (18.2% below fair value)
No single metric tells the full story. See the STU:UNC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
85GF Score
Get the complete analysis for STU:UNC
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:UNC has been successfully added to your 
